Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-06-26

AUTHORS

Thomas H. Cartwright, Monika Parisi, Janet L. Espirito, Thomas W. Wilson, Corey Pelletier, Manish Patel, Hani M. Babiker

ABSTRACT

BACKGROUND: The combination chemotherapy regimens of nab-paclitaxel plus gemcitabine (nab-p + G) and FOLFIRINOX (FFX) have each demonstrated improved survival compared with gemcitabine monotherapy in clinical trials for metastatic pancreatic cancer; however, limited comparative data exist. OBJECTIVE: The objective of this study was to compare patient characteristics and clinical outcomes including time to treatment failure and overall survival in patients with metastatic pancreatic cancer receiving first-line chemotherapy in the community. METHODS: We conducted a retrospective, multi-site, observational cohort study of patients with metastatic pancreatic cancer receiving first-line nab-p + G, FFX, or gemcitabine monotherapy between April 2013 and October 2015, using data from the iKnowMed electronic health record database. Patients on clinical trials or with other cancer diagnoses were excluded. Time to treatment failure and overall survival were assessed by Kaplan-Meier methods. RESULTS: Four hundred and eighty-six patients met selection criteria, 255 nab-p + G, 159 FFX, and 72 gemcitabine patients. Median age was 61, 68, and 73 years for FFX, nab-p + G, and gemcitabine patients, respectively (p < 0.01 for nab-p + G vs. FFX). Eastern Cooperative Oncology Group performance status of 0-1 was 91% for FFX, 77% for nab-p + G, and 68% for gemcitabine patients (p < 0.01 for nab-p + G vs. FFX). For the nab-p + G vs. FFX cohorts, respectively, time to treatment failure was 3.7 vs. 4.3 months (log-rank p = 0.25); and OS was 9.8 vs. 11.4 months (log-rank p = 0.38). Among patients with Eastern Cooperative Oncology Group performance status 0-1, time to treatment failure was 4.2 vs. 4.3 months (log-rank p = 0.47); and overall survival was 12.1 vs 11.4 months (log-rank p = 0.68). CONCLUSIONS: The nab-p + G patients were older and had worse performance status than FFX patients. Time to treatment failure and overall survival were not observed to be significantly different in first-line nab-p + G and FFX patients. Results were similar after stratifying by performance status. More... »

PAGES

149-159

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40801-018-0137-x

DOI

http://dx.doi.org/10.1007/s40801-018-0137-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1105122447

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29946913


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Florida Cancer Affiliates, 433 SW 10th St, Ocala, FL 34471 USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Florida Cancer Affiliates, 433 SW 10th St, Ocala, FL 34471 USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cartwright", 
        "givenName": "Thomas H.", 
        "id": "sg:person.01023134151.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023134151.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Celgene Corporation, Summit, NJ USA", 
          "id": "http://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "Celgene Corporation, Summit, NJ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Parisi", 
        "givenName": "Monika", 
        "id": "sg:person.014770424425.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014770424425.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "McKesson Specialty Health, The Woodlands, TX USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "McKesson Specialty Health, The Woodlands, TX USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Espirito", 
        "givenName": "Janet L.", 
        "id": "sg:person.01303513217.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303513217.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "McKesson Specialty Health, The Woodlands, TX USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "McKesson Specialty Health, The Woodlands, TX USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wilson", 
        "givenName": "Thomas W.", 
        "id": "sg:person.016051450446.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016051450446.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Celgene Corporation, Summit, NJ USA", 
          "id": "http://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "Celgene Corporation, Summit, NJ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pelletier", 
        "givenName": "Corey", 
        "id": "sg:person.01115204244.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115204244.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Celgene Corporation, Summit, NJ USA", 
          "id": "http://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "Celgene Corporation, Summit, NJ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Patel", 
        "givenName": "Manish", 
        "id": "sg:person.015566005025.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015566005025.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona Cancer Center, Tucson, AZ USA", 
          "id": "http://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "University of Arizona Cancer Center, Tucson, AZ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Babiker", 
        "givenName": "Hani M.", 
        "id": "sg:person.01113431302.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113431302.46"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10637-018-0598-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101900993", 
          "https://doi.org/10.1007/s10637-018-0598-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12029-017-0028-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092706859", 
          "https://doi.org/10.1007/s12029-017-0028-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-06-26", 
    "datePublishedReg": "2018-06-26", 
    "description": "BACKGROUND: The combination chemotherapy regimens of nab-paclitaxel plus gemcitabine (nab-p\u2009+\u2009G) and FOLFIRINOX (FFX) have each demonstrated improved survival compared with gemcitabine monotherapy in clinical trials for metastatic pancreatic cancer; however, limited comparative data exist.\nOBJECTIVE: The objective of this study was to compare patient characteristics and clinical outcomes including time to treatment failure and overall survival in patients with metastatic pancreatic cancer receiving first-line chemotherapy in the community.\nMETHODS: We conducted a retrospective, multi-site, observational cohort study of patients with metastatic pancreatic cancer receiving first-line nab-p\u2009+\u2009G, FFX, or gemcitabine monotherapy between April 2013 and October 2015, using data from the iKnowMed electronic health record database. Patients on clinical trials or with other cancer diagnoses were excluded. Time to treatment failure and overall survival were assessed by Kaplan-Meier methods.\nRESULTS: Four hundred and eighty-six patients met selection criteria, 255 nab-p\u2009+\u2009G, 159 FFX, and 72 gemcitabine patients. Median age was 61, 68, and 73\u00a0years for FFX, nab-p\u2009+\u2009G, and gemcitabine patients, respectively (p\u2009<\u20090.01 for nab-p\u2009+\u2009G vs. FFX). Eastern Cooperative Oncology Group performance status of 0-1 was 91% for FFX, 77% for nab-p\u2009+\u2009G, and 68% for gemcitabine patients (p\u2009<\u20090.01 for nab-p\u2009+\u2009G vs. FFX). For the nab-p\u2009+\u2009G vs. FFX cohorts, respectively, time to treatment failure was 3.7 vs. 4.3\u00a0months (log-rank p\u2009=\u20090.25); and OS was 9.8 vs. 11.4\u00a0months (log-rank p\u2009=\u20090.38). Among patients with Eastern Cooperative Oncology Group performance status 0-1, time to treatment failure was 4.2 vs. 4.3\u00a0months (log-rank p\u2009=\u20090.47); and overall survival was 12.1 vs 11.4\u00a0months (log-rank p\u2009=\u20090.68).\nCONCLUSIONS: The nab-p\u2009+\u2009G patients were older and had worse performance status than FFX patients. Time to treatment failure and overall survival were not observed to be significantly different in first-line nab-p\u2009+\u2009G and FFX patients. Results were similar after stratifying by performance status.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40801-018-0137-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1051855", 
        "issn": [
          "2199-1154", 
          "2198-9788"
        ], 
        "name": "Drugs - Real World Outcomes", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "keywords": [
      "metastatic pancreatic cancer", 
      "first-line nab", 
      "treatment failure", 
      "overall survival", 
      "pancreatic cancer", 
      "gemcitabine patients", 
      "performance status", 
      "gemcitabine monotherapy", 
      "clinical outcomes", 
      "clinical trials", 
      "Eastern Cooperative Oncology Group performance status 0", 
      "Eastern Cooperative Oncology Group performance status", 
      "US community oncology setting", 
      "electronic health record database", 
      "performance status 0", 
      "worse performance status", 
      "first-line chemotherapy", 
      "observational cohort study", 
      "Kaplan-Meier method", 
      "community oncology setting", 
      "large retrospective study", 
      "health record database", 
      "limited comparative data", 
      "status 0", 
      "line chemotherapy", 
      "nab-paclitaxel", 
      "combination chemotherapy", 
      "patient characteristics", 
      "cohort study", 
      "median age", 
      "improved survival", 
      "retrospective study", 
      "oncology setting", 
      "FOLFIRINOX", 
      "patients", 
      "record database", 
      "chemotherapy", 
      "cancer", 
      "NAbs", 
      "cancer diagnosis", 
      "months", 
      "survival", 
      "monotherapy", 
      "trials", 
      "outcomes", 
      "failure", 
      "status", 
      "selection criteria", 
      "gemcitabine", 
      "comparative data", 
      "cohort", 
      "diagnosis", 
      "study", 
      "age", 
      "OS", 
      "years", 
      "setting", 
      "time", 
      "data", 
      "criteria", 
      "database", 
      "objective", 
      "results", 
      "characteristics", 
      "community", 
      "method", 
      "iKnowMed electronic health record database", 
      "Cooperative Oncology Group performance status", 
      "Oncology Group performance status", 
      "Group performance status", 
      "FFX cohorts", 
      "Cooperative Oncology Group performance status 0", 
      "Oncology Group performance status 0", 
      "Group performance status 0", 
      "FFX patients"
    ], 
    "name": "Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting", 
    "pagination": "149-159", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1105122447"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40801-018-0137-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29946913"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40801-018-0137-x", 
      "https://app.dimensions.ai/details/publication/pub.1105122447"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_763.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40801-018-0137-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0137-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0137-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0137-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0137-x'


 

This table displays all metadata directly associated to this object as RDF triples.

195 TRIPLES      22 PREDICATES      103 URIs      93 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40801-018-0137-x schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Na48f4ee1e0724a9cb56de3582358e412
4 schema:citation sg:pub.10.1007/s10637-018-0598-5
5 sg:pub.10.1007/s12029-017-0028-5
6 schema:datePublished 2018-06-26
7 schema:datePublishedReg 2018-06-26
8 schema:description BACKGROUND: The combination chemotherapy regimens of nab-paclitaxel plus gemcitabine (nab-p + G) and FOLFIRINOX (FFX) have each demonstrated improved survival compared with gemcitabine monotherapy in clinical trials for metastatic pancreatic cancer; however, limited comparative data exist. OBJECTIVE: The objective of this study was to compare patient characteristics and clinical outcomes including time to treatment failure and overall survival in patients with metastatic pancreatic cancer receiving first-line chemotherapy in the community. METHODS: We conducted a retrospective, multi-site, observational cohort study of patients with metastatic pancreatic cancer receiving first-line nab-p + G, FFX, or gemcitabine monotherapy between April 2013 and October 2015, using data from the iKnowMed electronic health record database. Patients on clinical trials or with other cancer diagnoses were excluded. Time to treatment failure and overall survival were assessed by Kaplan-Meier methods. RESULTS: Four hundred and eighty-six patients met selection criteria, 255 nab-p + G, 159 FFX, and 72 gemcitabine patients. Median age was 61, 68, and 73 years for FFX, nab-p + G, and gemcitabine patients, respectively (p < 0.01 for nab-p + G vs. FFX). Eastern Cooperative Oncology Group performance status of 0-1 was 91% for FFX, 77% for nab-p + G, and 68% for gemcitabine patients (p < 0.01 for nab-p + G vs. FFX). For the nab-p + G vs. FFX cohorts, respectively, time to treatment failure was 3.7 vs. 4.3 months (log-rank p = 0.25); and OS was 9.8 vs. 11.4 months (log-rank p = 0.38). Among patients with Eastern Cooperative Oncology Group performance status 0-1, time to treatment failure was 4.2 vs. 4.3 months (log-rank p = 0.47); and overall survival was 12.1 vs 11.4 months (log-rank p = 0.68). CONCLUSIONS: The nab-p + G patients were older and had worse performance status than FFX patients. Time to treatment failure and overall survival were not observed to be significantly different in first-line nab-p + G and FFX patients. Results were similar after stratifying by performance status.
9 schema:genre article
10 schema:inLanguage en
11 schema:isAccessibleForFree true
12 schema:isPartOf N027f25066d47462dba05b367871ef8c8
13 Nc7125e7ca4544bfca9f5233c60188b5a
14 sg:journal.1051855
15 schema:keywords Cooperative Oncology Group performance status
16 Cooperative Oncology Group performance status 0
17 Eastern Cooperative Oncology Group performance status
18 Eastern Cooperative Oncology Group performance status 0
19 FFX cohorts
20 FFX patients
21 FOLFIRINOX
22 Group performance status
23 Group performance status 0
24 Kaplan-Meier method
25 NAbs
26 OS
27 Oncology Group performance status
28 Oncology Group performance status 0
29 US community oncology setting
30 age
31 cancer
32 cancer diagnosis
33 characteristics
34 chemotherapy
35 clinical outcomes
36 clinical trials
37 cohort
38 cohort study
39 combination chemotherapy
40 community
41 community oncology setting
42 comparative data
43 criteria
44 data
45 database
46 diagnosis
47 electronic health record database
48 failure
49 first-line chemotherapy
50 first-line nab
51 gemcitabine
52 gemcitabine monotherapy
53 gemcitabine patients
54 health record database
55 iKnowMed electronic health record database
56 improved survival
57 large retrospective study
58 limited comparative data
59 line chemotherapy
60 median age
61 metastatic pancreatic cancer
62 method
63 monotherapy
64 months
65 nab-paclitaxel
66 objective
67 observational cohort study
68 oncology setting
69 outcomes
70 overall survival
71 pancreatic cancer
72 patient characteristics
73 patients
74 performance status
75 performance status 0
76 record database
77 results
78 retrospective study
79 selection criteria
80 setting
81 status
82 status 0
83 study
84 survival
85 time
86 treatment failure
87 trials
88 worse performance status
89 years
90 schema:name Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting
91 schema:pagination 149-159
92 schema:productId N4acb9342dfc04c478752f4785ae1f51c
93 N900e3d92a8774c58a2c825f2345e2e26
94 Nc54622155d9040f48b89dc80174a537d
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105122447
96 https://doi.org/10.1007/s40801-018-0137-x
97 schema:sdDatePublished 2021-12-01T19:40
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher N90b562ceaa4c4aa99ff1e471cf1613ae
100 schema:url https://doi.org/10.1007/s40801-018-0137-x
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N027f25066d47462dba05b367871ef8c8 schema:issueNumber 3
105 rdf:type schema:PublicationIssue
106 N1e8f93f5d2ca4fddb61cdad292c37049 rdf:first sg:person.014770424425.96
107 rdf:rest N6faf53735baf4b7780bcc58426a64c25
108 N4acb9342dfc04c478752f4785ae1f51c schema:name doi
109 schema:value 10.1007/s40801-018-0137-x
110 rdf:type schema:PropertyValue
111 N6faf53735baf4b7780bcc58426a64c25 rdf:first sg:person.01303513217.59
112 rdf:rest N78fb60f623af4db4a3b265dcc051402d
113 N78fb60f623af4db4a3b265dcc051402d rdf:first sg:person.016051450446.94
114 rdf:rest Nc94ca5ddd33047998ff19794706e4bec
115 N809626a7e43547cfb7eaa3d10b6939f9 rdf:first sg:person.01113431302.46
116 rdf:rest rdf:nil
117 N900e3d92a8774c58a2c825f2345e2e26 schema:name pubmed_id
118 schema:value 29946913
119 rdf:type schema:PropertyValue
120 N90b562ceaa4c4aa99ff1e471cf1613ae schema:name Springer Nature - SN SciGraph project
121 rdf:type schema:Organization
122 Na48f4ee1e0724a9cb56de3582358e412 rdf:first sg:person.01023134151.36
123 rdf:rest N1e8f93f5d2ca4fddb61cdad292c37049
124 Nb08fdeafeb9c4106b54046f8502b914b rdf:first sg:person.015566005025.21
125 rdf:rest N809626a7e43547cfb7eaa3d10b6939f9
126 Nc54622155d9040f48b89dc80174a537d schema:name dimensions_id
127 schema:value pub.1105122447
128 rdf:type schema:PropertyValue
129 Nc7125e7ca4544bfca9f5233c60188b5a schema:volumeNumber 5
130 rdf:type schema:PublicationVolume
131 Nc94ca5ddd33047998ff19794706e4bec rdf:first sg:person.01115204244.09
132 rdf:rest Nb08fdeafeb9c4106b54046f8502b914b
133 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
134 schema:name Medical and Health Sciences
135 rdf:type schema:DefinedTerm
136 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
137 schema:name Oncology and Carcinogenesis
138 rdf:type schema:DefinedTerm
139 sg:journal.1051855 schema:issn 2198-9788
140 2199-1154
141 schema:name Drugs - Real World Outcomes
142 schema:publisher Springer Nature
143 rdf:type schema:Periodical
144 sg:person.01023134151.36 schema:affiliation grid-institutes:None
145 schema:familyName Cartwright
146 schema:givenName Thomas H.
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023134151.36
148 rdf:type schema:Person
149 sg:person.01113431302.46 schema:affiliation grid-institutes:grid.134563.6
150 schema:familyName Babiker
151 schema:givenName Hani M.
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113431302.46
153 rdf:type schema:Person
154 sg:person.01115204244.09 schema:affiliation grid-institutes:grid.419971.3
155 schema:familyName Pelletier
156 schema:givenName Corey
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115204244.09
158 rdf:type schema:Person
159 sg:person.01303513217.59 schema:affiliation grid-institutes:None
160 schema:familyName Espirito
161 schema:givenName Janet L.
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303513217.59
163 rdf:type schema:Person
164 sg:person.014770424425.96 schema:affiliation grid-institutes:grid.419971.3
165 schema:familyName Parisi
166 schema:givenName Monika
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014770424425.96
168 rdf:type schema:Person
169 sg:person.015566005025.21 schema:affiliation grid-institutes:grid.419971.3
170 schema:familyName Patel
171 schema:givenName Manish
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015566005025.21
173 rdf:type schema:Person
174 sg:person.016051450446.94 schema:affiliation grid-institutes:None
175 schema:familyName Wilson
176 schema:givenName Thomas W.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016051450446.94
178 rdf:type schema:Person
179 sg:pub.10.1007/s10637-018-0598-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101900993
180 https://doi.org/10.1007/s10637-018-0598-5
181 rdf:type schema:CreativeWork
182 sg:pub.10.1007/s12029-017-0028-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092706859
183 https://doi.org/10.1007/s12029-017-0028-5
184 rdf:type schema:CreativeWork
185 grid-institutes:None schema:alternateName Florida Cancer Affiliates, 433 SW 10th St, Ocala, FL 34471 USA
186 McKesson Specialty Health, The Woodlands, TX USA
187 schema:name Florida Cancer Affiliates, 433 SW 10th St, Ocala, FL 34471 USA
188 McKesson Specialty Health, The Woodlands, TX USA
189 rdf:type schema:Organization
190 grid-institutes:grid.134563.6 schema:alternateName University of Arizona Cancer Center, Tucson, AZ USA
191 schema:name University of Arizona Cancer Center, Tucson, AZ USA
192 rdf:type schema:Organization
193 grid-institutes:grid.419971.3 schema:alternateName Celgene Corporation, Summit, NJ USA
194 schema:name Celgene Corporation, Summit, NJ USA
195 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...